KRAS and adenocarcinoma: Dacic et al. [70] examined the microRNA expressions in lung adenocarcinomas with different driver mutations, focusing on EGFR and KRAS mutation, using two EGFR-mutant, two KRAS-mutant, and two EGFR-wild-type/KRAS-wild-type adenocarcinomas and confirmed differentially expressed microRNAs in a validation set of 18 adenocarcinomas.